BioMarin Pharma (BMRN) Misses Q4 EPS by 7c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.37 --0%
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +1,008.3%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.30), $0.07 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $358.3 million versus the consensus estimate of $351.62 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.48 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
- AppLovin drops 3% as Edgewater analyst warns of stalled market share growth
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
